Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation
Authors: Benjamin A. Rodwin
Journal: Annals of Internal Medicine (2021)

LettersOctober 2021Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial FibrillationBenjamin A. Rodwin, MDBenjamin A. Rodwin, MDVA Connecticut Healthcare System and Yale School of Medicine, New Haven, ConnecticutSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0564 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: I enjoyed Dawwas and colleagues' recent article (1) but am concerned that their title, “Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation” [emphasis added], is misleading. The American College of Cardiology/American Heart Association reports, “Valvular [atrial fibrillation (AF)] generally refers to AF in the setting of moderate-to-severe mitral stenosis (potentially requiring surgical intervention) or in the presence of an artificial (mechanical) heart valve.” (2). Dawwas and colleagues' article explicitly excludes patients with mechanical heart valves, and most of the patients with mitral disease had “other unspecified mitral valve disease.”The ...References1. Dawwas GK, Dietrich E, Cuker A, et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation. A population-based cohort study. Ann Intern Med. 2021;174:910-9. [PMID: 33780291] doi:10.7326/M20-6194 LinkGoogle Scholar2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-51. [PMID: 30686041] doi:10.1161/CIR.0000000000000665 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: VA Connecticut Healthcare System and Yale School of Medicine, New Haven, ConnecticutDisclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0564. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation Ghadeer K. Dawwas , Eric Dietrich , Adam Cuker , Geoffrey D. Barnes , Charles E. Leonard , and James D. Lewis Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation Ghadeer K. Dawwas , Geoffrey D. Barnes , Adam Cuker , and James D. Lewis Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation Ishak A. Mansi , Sujata Bhushan , and David E. Albracht Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation Siddharth Shah and Jalaj Garg Metrics Cited byTrends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019) October 2021Volume 174, Issue 10Page: 1488-1489 ePublished: 19 October 2021 Issue Published: October 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...